Form 4: MapLight CMO Erin Foff Executes Planned Stock Sale
Statement of Changes in Beneficial Ownership
Chief Medical Officer Erin Foff sold 50,280 shares of MapLight Therapeutics common stock via a pre-arranged 10b5-1 trading plan.
Summary
- Erin Foff, Chief Medical Officer of MapLight Therapeutics, sold a total of 50,280 shares of voting common stock between May 4, 2026, and May 6, 2026.
- The sales were executed at weighted average prices ranging from $27.50 to $30.08 per share.
- Following these transactions, the reporting person retains beneficial ownership of 350,497 shares.
- All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and represent standard executive financial management rather than a reaction to company performance.
Positives
- The sales were executed under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.
Negatives
- The transaction represents a reduction in the executive's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's near-term valuation.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance events and generally do not reflect a change in company strategy or fundamental outlook.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for biotech executives to manage personal liquidity while maintaining compliance with SEC regulations.
Stakeholder Impact
- Shareholders should note the reduction in insider holdings, though the pre-planned nature of the sale mitigates concerns regarding potential negative sentiment.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 2025-12-29 | Adoption date of the Rule 10b5-1 trading plan. |
| 2026-05-04 | Earliest transaction date of the reported sales. |
| 2026-05-06 | Final transaction date and filing date of the Form 4. |
Keywords
MapLight Therapeutics, MPLT, Insider Trading, Form 4, Chief Medical Officer, Equity Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.